HomeCompareEIPFX vs MRK

EIPFX vs MRK: Dividend Comparison 2026

EIPFX yields 12.89% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIPFX wins by $16.0K in total portfolio value
10 years
EIPFX
EIPFX
● Live price
12.89%
Share price
$20.00
Annual div
$2.58
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.7K
Annual income
$2,874.23
Full EIPFX calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — EIPFX vs MRK

📍 EIPFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIPFXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIPFX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIPFX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIPFX
Annual income on $10K today (after 15% tax)
$1,095.65/yr
After 10yr DRIP, annual income (after tax)
$2,443.10/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, EIPFX beats the other by $1,635.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIPFX + MRK for your $10,000?

EIPFX: 50%MRK: 50%
100% MRK50/50100% EIPFX
Portfolio after 10yr
$38.7K
Annual income
$1,912.26/yr
Blended yield
4.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EIPFX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIPFX buys
0
MRK buys
0
No recent congressional trades found for EIPFX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIPFXMRK
Forward yield12.89%3.25%
Annual dividend / share$2.58$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$46.7K$30.7K
Annual income after 10y$2,874.23$950.29
Total dividends collected$20.6K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EIPFX vs MRK ($10,000, DRIP)

YearEIPFX PortfolioEIPFX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,989$1,289.00$11,192$351.54+$797.00EIPFX
2$14,273$1,444.28$12,524$392.70+$1.7KEIPFX
3$16,878$1,606.89$14,015$438.65+$2.9KEIPFX
4$19,836$1,775.97$15,682$489.96+$4.2KEIPFX
5$23,175$1,950.61$17,547$547.23+$5.6KEIPFX
6$26,927$2,129.88$19,632$611.16+$7.3KEIPFX
7$31,125$2,312.82$21,963$682.53+$9.2KEIPFX
8$35,802$2,498.47$24,571$762.18+$11.2KEIPFX
9$40,994$2,685.91$27,486$851.08+$13.5KEIPFX
10$46,738$2,874.23$30,745$950.29+$16.0KEIPFX

EIPFX vs MRK: Complete Analysis 2026

EIPFXStock

The investment seeks to provide a high level of total shareholder return that is balanced between current income and growth; it seeks low volatility as a secondary objective. Under normal market conditions, the fund pursues its objectives by investing primarily in a diversified portfolio of equity securities of issuers in the energy industry ("Energy Companies") that seek to pay out as dividends or distributions a portion of income or distributable cash flow in excess of the average for listed equities as a whole. It concentrates its investments in the Energy Industry and may invest without limit in Energy Companies of any market capitalization.

Full EIPFX Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this EIPFX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIPFX vs SCHDEIPFX vs JEPIEIPFX vs OEIPFX vs KOEIPFX vs MAINEIPFX vs JNJEIPFX vs ABBVEIPFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.